PE20121396A1 - Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol - Google Patents

Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol

Info

Publication number
PE20121396A1
PE20121396A1 PE2012000865A PE2012000865A PE20121396A1 PE 20121396 A1 PE20121396 A1 PE 20121396A1 PE 2012000865 A PE2012000865 A PE 2012000865A PE 2012000865 A PE2012000865 A PE 2012000865A PE 20121396 A1 PE20121396 A1 PE 20121396A1
Authority
PE
Peru
Prior art keywords
formoterol
bromide
pharmaceutical composition
composition including
glycopyronium
Prior art date
Application number
PE2012000865A
Other languages
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20121396A1 publication Critical patent/PE20121396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE BROMURO DE GLICOPIRRONIO Y FORMOTEROL O UNA SAL DEL MISMO, DISUELTOS EN UN PROPELENTE DE HIDROFLUOROALCANO (HFA) Y UN COSOLVENTE TAL COMO ETANOL, DONDE EL BROMURO DE GLICOPIRRONIO SE ENCUENTRA EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,14% (P/P) Y EL FORMOTEROL EN UNA CONCENTRACION DE ENTRE 0,005% Y 0,07% (P/P). TAMBIEN COMPRENDE UNO O MAS INGREDIENTES FARMACEUTICAMENTE ACTIVOS SELECCIONADOS DE AGONISTAS BETA-2, CORTICOESTEROIDES TALES COMO EL DIPROPIONATO DE BECLOMETASONA, AGENTES ANTIMUSCARINICOS E INHIBIDORES DE FOSFODIESTERASA (IV). DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS, INCLUYENDO EPOC
PE2012000865A 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol PE20121396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23

Publications (1)

Publication Number Publication Date
PE20121396A1 true PE20121396A1 (es) 2012-10-24

Family

ID=42107420

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000787A PE20160853A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
PE2012000865A PE20121396A1 (es) 2009-12-23 2010-12-22 Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000787A PE20160853A1 (es) 2009-12-23 2010-12-22 Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)

Country Status (40)

Country Link
US (3) US20110150782A1 (es)
EP (1) EP2515855B3 (es)
JP (2) JP5914354B2 (es)
KR (2) KR101757951B1 (es)
CN (2) CN104055765B (es)
AR (2) AR079726A1 (es)
AU (3) AU2010334859A1 (es)
BR (1) BR112012015337B8 (es)
CA (1) CA2785321C (es)
CL (1) CL2012001705A1 (es)
CO (1) CO6541628A2 (es)
CY (2) CY1115116T1 (es)
DK (1) DK2515855T6 (es)
EA (2) EA027778B1 (es)
ES (1) ES2468840T7 (es)
FI (2) FIC20170064I1 (es)
GE (1) GEP20156311B (es)
HR (1) HRP20140582T4 (es)
HU (1) HUS1800001I1 (es)
IL (1) IL260932B (es)
LT (1) LTC2515855I2 (es)
LU (1) LUC00060I2 (es)
MA (1) MA33823B1 (es)
MX (1) MX2012006878A (es)
MY (1) MY156949A (es)
NL (1) NL300923I2 (es)
NO (1) NO2018001I1 (es)
NZ (1) NZ600790A (es)
PE (2) PE20160853A1 (es)
PH (1) PH12012501066A1 (es)
PL (1) PL2515855T6 (es)
PT (1) PT2515855E (es)
RS (1) RS53391B2 (es)
SG (1) SG181868A1 (es)
SI (1) SI2515855T1 (es)
TN (1) TN2012000269A1 (es)
TW (1) TWI495468B (es)
UA (1) UA113832C2 (es)
WO (1) WO2011076843A2 (es)
ZA (1) ZA201204615B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
UA113832C2 (xx) * 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
EP2515853B1 (en) * 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
EP2749283A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and olodaterol
RU2629085C2 (ru) * 2011-10-11 2017-08-24 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Кристаллические микрочастицы бета-агониста, покрытые жирной кислотой
WO2014064410A2 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical composition
HUE053957T2 (hu) 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra
LT3096737T (lt) * 2013-12-30 2018-06-11 Chiesi Farmaceutici S.P.A. Stabili glikopironio bromido ir formoterolio derinio suspausto aerozolio tirpalo kompozicija
EP3384898A1 (en) * 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
PT3628331T (pt) * 2015-11-16 2021-10-20 Chiesi Farm Spa Processo para preparar uma formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3436115B1 (en) 2016-03-31 2021-07-28 Chiesi Farmaceutici S.p.A. Aerosol inhalation device
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
MX384545B (es) 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica
ES2904823T3 (es) * 2016-09-19 2022-04-06 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de tiotropio
MX387723B (es) 2016-09-19 2025-03-18 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
CA3060020A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN110612095A (zh) * 2017-05-11 2019-12-24 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
FI4188327T3 (fi) 2020-07-31 2025-07-25 Chemo Res S L Yhdistelmähoito inhalaatioannosteluun
IL301617A (en) 2020-10-09 2023-05-01 Chiesi Farm Spa A pharmaceutical formulation for pressurised metered dose inhaler
US20250302742A1 (en) 2022-05-27 2025-10-02 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
IL317170A (en) 2022-05-27 2025-01-01 Chiesi Farm Spa Pharmaceutical formulation for pressurized metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SK280911B6 (sk) 1992-12-09 2000-09-12 Boehringer Ingelheim Pharmaceuticals, Inc. Farmaceutický prostriedok
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
NZ528640A (en) 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP3384931B1 (en) 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
MXPA05006383A (es) 2002-12-16 2005-08-29 Boehringer Ingelheim Pharma Formulaciones de soluciones de hidrofluorocarburo que contienen tiotropio.
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CN101232913B (zh) 2005-08-01 2011-04-06 阿斯利康(瑞典)有限公司 吸入器阀
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2008314628B2 (en) 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
UA113832C2 (xx) * 2009-12-23 2017-03-27 Комбінаційна терапія для хозл
WO2011076842A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
ES2467928T3 (es) * 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
EP2515853B1 (en) * 2009-12-23 2014-03-19 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
HUE053957T2 (hu) * 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra
LT3096737T (lt) 2013-12-30 2018-06-11 Chiesi Farmaceutici S.P.A. Stabili glikopironio bromido ir formoterolio derinio suspausto aerozolio tirpalo kompozicija
EP3384898A1 (en) * 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
JP5914354B2 (ja) 2016-05-11
BR112012015337B1 (pt) 2021-05-04
AU2016234895C1 (en) 2026-02-19
AU2010334859A1 (en) 2012-07-12
BR112012015337B8 (pt) 2021-05-25
CY2017047I1 (el) 2018-04-04
CA2785321C (en) 2018-08-21
CO6541628A2 (es) 2012-10-16
KR20170040392A (ko) 2017-04-12
CL2012001705A1 (es) 2012-09-28
WO2011076843A2 (en) 2011-06-30
MA33823B1 (fr) 2012-12-03
NL300923I2 (en) 2019-07-22
US20110150782A1 (en) 2011-06-23
JP6283388B2 (ja) 2018-02-21
JP2013515696A (ja) 2013-05-09
ZA201204615B (en) 2013-09-25
NO2018001I2 (no) 2018-01-10
AU2016234895B2 (en) 2018-02-01
AU2016234895A1 (en) 2016-10-13
AR079726A1 (es) 2012-02-15
TW201129359A (en) 2011-09-01
LTC2515855I2 (lt) 2019-05-10
PT2515855E (pt) 2014-06-11
SG181868A1 (en) 2012-07-30
MY156949A (en) 2016-04-15
NL300923I1 (en) 2018-01-17
PL2515855T6 (pl) 2023-12-18
JP2016145239A (ja) 2016-08-12
IL260932B (en) 2021-04-29
CN102665679A (zh) 2012-09-12
PL2515855T3 (pl) 2014-08-29
CY2017047I2 (el) 2018-04-04
RS53391B (sr) 2014-10-31
HUS1800001I1 (hu) 2018-02-28
US11389401B2 (en) 2022-07-19
US20150328144A1 (en) 2015-11-19
TN2012000269A1 (en) 2013-12-12
EP2515855A2 (en) 2012-10-31
AU2018202998A1 (en) 2018-05-17
HRP20140582T4 (hr) 2023-06-09
PH12012501066A1 (en) 2016-03-02
FIC20170064I1 (fi) 2017-12-29
CN104055765A (zh) 2014-09-24
EA201290375A1 (ru) 2013-01-30
HK1174566A1 (en) 2013-06-14
CN104055765B (zh) 2016-11-23
EP2515855B3 (en) 2023-05-03
US20190046433A1 (en) 2019-02-14
DK2515855T3 (da) 2014-06-30
LTPA2018001I1 (lt) 2018-02-12
UA113832C2 (xx) 2017-03-27
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
PE20160853A1 (es) 2016-09-14
EP2515855B1 (en) 2014-04-02
MX2012006878A (es) 2012-07-04
EA021917B1 (ru) 2015-09-30
ES2468840T3 (es) 2014-06-17
EA201590179A1 (ru) 2015-09-30
CA2785321A1 (en) 2011-06-30
EA027778B1 (ru) 2017-08-31
CY1115116T1 (el) 2016-12-14
NO2018001I1 (no) 2018-01-10
HK1197036A1 (en) 2015-01-02
HRP20140582T1 (hr) 2014-08-01
SI2515855T1 (sl) 2014-08-29
US10159645B2 (en) 2018-12-25
WO2011076843A3 (en) 2011-12-01
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (es) 2018-03-16
NZ600790A (en) 2014-09-26
CN102665679B (zh) 2014-11-26
LUC00060I1 (es) 2018-01-18
ES2468840T7 (es) 2023-11-29
FI2515855T6 (fi) 2023-06-02
GEP20156311B (en) 2015-07-10
DK2515855T6 (da) 2023-06-06
KR20120103653A (ko) 2012-09-19
RS53391B2 (sr) 2023-09-29
TWI495468B (zh) 2015-08-11

Similar Documents

Publication Publication Date Title
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
PE20160997A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
JP2010132695A5 (es)
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
EP4548972A3 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PE20091672A1 (es) Nueva dosificacion y formulacion
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PE20160155A1 (es) Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
PE20091392A1 (es) Composiciones farmaceuticas como agentes antiinflamatorios
PE20121467A1 (es) Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
PE20081789A1 (es) Composicion farmaceutica que contiene aclidino
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
RU2012125966A (ru) Комбинированное лечение хронического обструктивного заболевания легких
PE20071231A1 (es) Formulaciones farmaceuticas de pleconaril
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
BR112014004879A2 (pt) uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
PE20170073A1 (es) Combinaciones de bromuro de tiotropio, formoterol y budesonida para el tratamiento de la copd
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
CO7170176A2 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo
ECSP11011323A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento.

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FC Refusal